Results 141 to 150 of about 24,145,261 (292)

Targeting the CD47–SIRPα phagocytic checkpoint in cancer: Biology, translational opportunities, and next‐generation therapeutic strategies

open access: yesSmart Molecules, EarlyView.
The CD47–SIRPα axis has emerged as a critical innate immune checkpoint that suppresses macrophage‐mediated phagocytosis through a canonical “don't eat me” signal and enables tumor immune evasion. We comprehensively summarize the structural and biological features of CD47 and the molecular mechanisms underlying CD47‐mediated regulation of phagocytosis ...
Ruimei Zhou   +4 more
wiley   +1 more source

Artificial intelligence empowers targeted protein degradation: Core technological innovations, multi‐scenario applications, and translational prospects

open access: yesSmart Molecules, EarlyView.
AI is transforming TPD by improving the design, prediction, and optimization of degraders such as PROTACs, molecular glues, and LYTACs. This review summarizes key AI‐driven advances, highlights applications across drug discovery stages, and discusses remaining challenges and future directions for accelerating the development of therapies against ...
Shuanglin Qin   +10 more
wiley   +1 more source

Thrombocytosis and tumour distribution predict outcome in dogs with hepatocellular carcinoma: A multi‐institutional retrospective analysis

open access: yesVeterinary Record, EarlyView.
Abstract Background Hepatocellular carcinoma (HCC) is the most common canine hepatobiliary tumour. This study aimed to determine which criteria influenced outcome of HCC in a modern population of dogs across eight institutions. Methods The medical records of 106 dogs with HCC were retrospectively reviewed.
Emily A. Janik   +2 more
wiley   +1 more source

Pancreatic Panniculitis as the First Presentation of Pancreatic Adenocarcinoma

open access: yes
JEADV Clinical Practice, EarlyView.
Claudine Howard‐James   +2 more
wiley   +1 more source

YTHDF2 in hepatocellular carcinoma: Bridging m6A modification and cancer progression

open access: yesVIEW, EarlyView.
Abstract YTH N6‐methyladenosine RNAbinding protein F2 (YTHDF2) is an N6‐methyladenosine (m6A) reader protein that mainly regulates the stability of methylated transcripts through mRNA decay. In the liver, YTHDF2 is involved in metabolic homeostasis, oxidative stress responses, and immune regulation.
Sijie Zang   +7 more
wiley   +1 more source

Epiphora: A Structured Diagnostic Approach for the Otolaryngologist

open access: yesWorld Journal of Otorhinolaryngology - Head and Neck Surgery, EarlyView.
ABSTRACT Introduction Epiphora, or excessive tearing, has historically been predominantly managed by ophthalmologists. However, as there is substantial overlap between ophthalmic and otolaryngologic anatomy and pathology that may contribute to epiphora, patients with this symptom often present to otolaryngologists as well.
Luke M. O'Neil   +7 more
wiley   +1 more source

Primary Diffuse Large Cell Lymphoma of the Bladder: Case Report and Literature Review

open access: yesMiddle East Journal of Cancer, 2017
Most bladder tumors are epithelial in origin. Nonepithelial cancers are rarely located in the bladder. Sarcomas are the most common malignancies among nonepithelial cancers. Primary bladder lymphoma is rare and mostly low grade. Here, we have reported
Mansour Ansari   +8 more
doaj  

Review on enhancing clinical decision support system using machine learning

open access: yesCAAI Transactions on Intelligence Technology, EarlyView.
Abstract Clinical decision‐making is a complex patient‐centred process. For an informed clinical decision, the input data is very thorough ranging from detailed family history, environmental history, social history, health‐risk assessments, and prior relevant medical cases.
Anum Masood   +4 more
wiley   +1 more source

Unusual manifestation of diffuse large B-cell lymphoma [PDF]

open access: yesPolish Archives of Internal Medicine, 2020
Izabela, Rubisz   +3 more
openaire   +3 more sources

Emerging Therapies for Diffuse Large B-Cell Lymphoma

open access: yes
Emerging Therapies for Diffuse Large B-Cell Lymphoma. Dr. Joseph DiTursi, Hematology & Oncology Department, Rochester Regional Health Objectives: Understand demographics, diagnosis, and initial workup of diffuse large B-Cell lymphoma (DLBCL) Understand
DiTursi, Joseph
core  

Home - About - Disclaimer - Privacy